Literature DB >> 21068540

CIP2A expression and localization in oral carcinoma and dysplasia.

Joseph Katz1, Andrew Jakymiw, Monet K Ducksworth, Carol M Stewart, Indraneel Bhattacharyya, Seunghee Cha, Edward K L Chan.   

Abstract

AIMS: Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity resulting in severe morbidity and mortality. To date only few proteins have been suggested as potential biomarkers or targets for this type of cancer. Cancerous inhibitor of PP2A (CIP2A) is a protein expressed in epithelial tissues that stabilizes the oncogene c-Myc and causes cell transformation. This study was designed to investigate the expression of CIP2A in OSCC cell lines and tissues representing human normal, dysplasia and OSCC.
METHODS: Using quantitative real time PCR, mRNA quantification for CIP2A was performed in a primary gingival cell line and OSCCs CAL 27 and SCC-25. Paraffin embedded human specimen classified as normal, dysplastic or OSCC were immunohistochemically stained for CIP2A expression. EGFR and CIP2A were also stained by immunofluorescence for co-localization. Samples of human normal oral tissue and OSCC were studied by PCR for mRNA expression of CIP2A.
RESULTS: CIP2A was significantly increased in the human carcinoma cell lines compared to the primary gingival cell line. CIP2A was overexpressed in the human oral dysplasia and OSCC tissues compared to normal oral tissues. CIP2A was also preferentially localized in the dysplastic and OSCC epithelial areas compared to EGFR that was expressed mainly in areas of relatively normal epithelium and in dysplastic tissues above the basal layers.
CONCLUSIONS: CIP2A may play a significant role in oral malignant transformation and therefore, it may be a potential target for chemotherapy of OSCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068540      PMCID: PMC3230513          DOI: 10.4161/cbt.10.7.12895

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  18 in total

1.  Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation.

Authors:  Omar Kujan; Ammar Khattab; Richard J Oliver; Stephen A Roberts; Nalin Thakker; Philip Sloan
Journal:  Oral Oncol       Date:  2006-08-22       Impact factor: 5.337

2.  Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.

Authors:  Yukihiro Hiraishi; Takeshi Wada; Ken Nakatani; Kenji Negoro; Shigeyuki Fujita
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

3.  Interobserver reliability in the histopathologic diagnosis of oral pre-malignant and malignant lesions.

Authors:  Dena J Fischer; Joel B Epstein; Thomas H Morton; Stephen M Schwartz
Journal:  J Oral Pathol Med       Date:  2004-02       Impact factor: 4.253

4.  MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Authors:  Anchit Khanna; Camilla Böckelman; Annabrita Hemmes; Melissa R Junttila; Jan-Patrik Wiksten; Mikael Lundin; Siina Junnila; Daniel J Murphy; Gerard I Evan; Caj Haglund; Jukka Westermarck; Ari Ristimäki
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

5.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

6.  Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

Authors:  Linda Soo Hoo; Jianying Y Zhang; Edward K L Chan
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

7.  Surveillance for cancers associated with tobacco use--United States, 1999-2004.

Authors:  Sherri L Stewart; Cheryll J Cardinez; Lisa C Richardson; Leslie Norman; Rachel Kaufmann; Terry F Pechacek; Trevor D Thompson; Hannah K Weir; Susan A Sabatino
Journal:  MMWR Surveill Summ       Date:  2008-09-05

Review 8.  Multiple pathways regulated by the tumor suppressor PP2A in transformation.

Authors:  Jukka Westermarck; William C Hahn
Journal:  Trends Mol Med       Date:  2008-03-10       Impact factor: 11.951

Review 9.  Mechanisms of MYC stabilization in human malignancies.

Authors:  Melissa R Junttila; Jukka Westermarck
Journal:  Cell Cycle       Date:  2007-12-29       Impact factor: 4.534

Review 10.  Diagnostic aids in the screening of oral cancer.

Authors:  Stefano Fedele
Journal:  Head Neck Oncol       Date:  2009-01-30
View more
  21 in total

1.  Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Michelle Pusey; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-04-02

2.  Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.

Authors:  Xinxin Liu; Yurong Chai; Jitian Li; Pengfei Ren; Mei Liu; Liping Dai; Wei Qian; Wenjie Li; Jian-Ying Zhang
Journal:  Tumour Biol       Date:  2014-01-08

3.  CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.

Authors:  Mo Zhai; Lin Cong; Yaxin Han; Guanjun Tu
Journal:  Tumour Biol       Date:  2013-09-08

4.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

5.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

6.  Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.

Authors:  Chun-Yu Liu; Chung-Wai Shiau; Hsin-Yu Kuo; Hsiang-Po Huang; Ming-Huang Chen; Cheng-Hwai Tzeng; Kuen-Feng Chen
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  CIP2A expression and prognostic role in patients with esophageal adenocarcinoma.

Authors:  Tuomo Rantanen; Tuuli Kauttu; Jonne Åkerla; Teemu Honkanen; Leena Krogerus; Jarmo Salo; Timo Paavonen; Niku Oksala
Journal:  Med Oncol       Date:  2013-08-08       Impact factor: 3.064

8.  Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Valerie Sodi; Lyndi M Rice
Journal:  Transcription       Date:  2012-11-01

9.  CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Authors:  Ling-Ming Tseng; Chun-Yu Liu; Kung-Chi Chang; Pei-Yi Chu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2012-04-26       Impact factor: 6.466

10.  Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.

Authors:  Hyun Min Jung; Rushi S Patel; Brittany L Phillips; Hai Wang; Donald M Cohen; William C Reinhold; Lung-Ji Chang; Li-Jun Yang; Edward K L Chan
Journal:  Mol Biol Cell       Date:  2013-04-03       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.